我們已在上線！進一步了解

Precipio

PRPO

市值 US$3827萬

21.38 USD

-1.16

5.15%

收盤時已更新 10月16日下午4:00 EDT

1天

-5.15%

5天

-6.64%

1個月

-19.8%

3個月

-9.71%

6個月

-26.28%

今年迄今

-10.24%

1年

14.64%

5年

-58.24%

10年

-98.81%

關於： Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

員工： 71

醫療保健診斷與研究

新聞

正面

中性

負面

市場情緒 3個月

正面 42.9%

中性 57.1%

負面 0%

Precipio: Management Dreams Big, Institutions Have A Toe In

Precipio is an established laboratory services provider in cancer diagnostics and has launched a razor and razor blade model for facilities to test their own samples on site. 16.6% of the stock is held by officers and directors. Vanguard took an initial position, and BlackRock added to its position in Q1 2026. The company is small, and management is thin. It has turned to a distributor model to reach new clients.

Precipio: Management Dreams Big, Institutions Have A Toe In

Zacks Investment Research

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Zacks Investment Research

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Zacks Investment Research

Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong

PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.

Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong

Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript

Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript

Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript

Precipio Announces Q2-2026 Financial Results

Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position

Precipio Announces Q2-2026 Financial Results

Precipio Announces Q2-2026 Shareholder Update Call

NEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET.

Precipio Announces Q2-2026 Shareholder Update Call

Zacks Investment Research

PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?

Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.

PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting.

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Precipio to Present at the Planet MicroCap Las Vegas

NEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of Precipio will be hosting the presentation and answering questions at the conclusion.

Precipio to Present at the Planet MicroCap Las Vegas

查看新聞排名

價格圖表採用Lightweight Charts™實作